<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
<Article>
<Journal>
<PublisherName>isfcppharmaspire</PublisherName>
<JournalTitle>Pharmaspire</JournalTitle>
<PISSN>C</PISSN>
<EISSN>o</EISSN>
<Volume-Issue>Volume 15, Issue 02, 2023</Volume-Issue>
<PartNumber/>
<IssueTopic>Multidisciplinary</IssueTopic>
<IssueLanguage>English</IssueLanguage>
<Season>April- June</Season>
<SpecialIssue>N</SpecialIssue>
<SupplementaryIssue>N</SupplementaryIssue>
<IssueOA>Y</IssueOA>
<PubDate>
<Year>2023</Year>
<Month>09</Month>
<Day>7</Day>
</PubDate>
<ArticleType>Pharmacology</ArticleType>
<ArticleTitle>Current challenges in the diagnosis and treatment of obsessive-compulsive disorder</ArticleTitle>
<SubTitle/>
<ArticleLanguage>English</ArticleLanguage>
<ArticleOA>Y</ArticleOA>
<FirstPage>70</FirstPage>
<LastPage>73</LastPage>
<AuthorList>
<Author>
<FirstName>Aditi</FirstName>
<LastName>Giri</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>N</CorrespondingAuthor>
<ORCID/>
<FirstName>Sidharth</FirstName>
<LastName>Mehan</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
</Author>
</AuthorList>
<DOI>10.56933/Pharmaspire.2023.15112</DOI>
<Abstract>This comprehensive review examines the current challenges in the diagnosis and treatment of obsessive compulsive disorder (OCD), a complex psychiatric condition affecting a significant portion of the global population. The challenges in diagnosis, including delayed diagnosis, stigma, misdiagnosis, underdiagnosis, and the difficulties posed by comorbidity, are discussed in depth. Further, the review highlights the obstacles in OCD treatment, such as suboptimal responses to first-line treatments, medication side effects, difficulties accessing treatment, and the heterogeneity of OCD. The paper includes illustrative case studies that shed light on the real-world implications of these challenges. Promising strategies and future directions to overcome these challenges are also explored, emphasizing the need for early and accurate diagnosis, enhanced treatment efficacy, improved access to care, and continuous research to deepen our understanding of OCD. Ultimately, this review advocates for a multi-faceted approach that includes improved diagnostic tools, personalized treatment plans, digital therapy platforms, and robust policies to improve mental health coverage. Despite the current challenges, advancements in understanding OCD and in the development of diagnostic tools and treatments provide an optimistic view of the future of OCD diagnosis and treatment.</Abstract>
<AbstractLanguage>English</AbstractLanguage>
<Keywords>Biomarkers, Diagnosis, Obsessive-compulsive disorder, Patient compliance</Keywords>
<URLs>
<Abstract>https://isfcppharmaspire.com/ubijournal-v1copy/journals/abstract.php?article_id=14809&title=Current challenges in the diagnosis and treatment of obsessive-compulsive disorder</Abstract>
</URLs>
<References>
<ReferencesarticleTitle>References</ReferencesarticleTitle>
<ReferencesfirstPage>16</ReferencesfirstPage>
<ReferenceslastPage>19</ReferenceslastPage>
<References>1. Richter PM, Ramos RT. Obsessive-compulsive disorder. Continuum (Minneap Minn) 2018;24(3 Behavioral Neurology and Psychiatry):828-44.
2. Gupta R, Mehan S, Sethi P, Prajapati A, Alshammari A, Alharbi M, et al. Smo-Shh agonist Purmorphamine prevents neurobehavioral and neurochemical defects in 8-OH-DPAT- induced experimental model of obsessive compulsive disorder. Brain Sci 2022;12:342.
3. Torres AR, Prince MJ, Bebbington PE, Bhugra DK, Brugha TS, Farrell M, et al. Obsessive-compulsive disorder: Prevalence, comorbidity, impact, and help seeking in the British National Psychiatric Morbidity Survey of 2000. Am J Psychiatry 2017;163:1978-85.
4. Hadi F, Kashefinejad S, Kamalzadeh L, Hoobehfekr S, Shalbafan M. Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: A systematic review and meta-analysis. BMC Pharmacol Toxicol 2021;22:69.
5. Fineberg NA, Reghunandanan S, Simpson HB, Phillips KA, Richter MA, Matthews K, et al. Obsessive compulsive disorder (OCD): Practical strategies for pharmacological and somatic treatment in adults. Psychiatry Res 2015;227:114-25.
6. Dell’Osso B, Benatti B, Buoli M, Altamura AC, Marazziti D, Hollander E, et al. The influence of age at onset and duration of illness on long-term outcome in patients with obsessive-compulsive disorder: A report from the International College of Obsessive- Compulsive Spectrum Disorders (ICOCS). Eur Neuropsychopharmacol 2013;23:865-71.
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Publishing; 2013.
8. Torres AR, Ramos-Cerqueira AT, Ferrand;atilde;o YA, Fontenelle LF, do Rosand;aacute;rio MC, Miguel EC. Suicidality in obsessive-compulsive disorder: Prevalence and relation to symptom dimensions and comorbid conditions. J Clin Psychiatry 2015;72:17-26.
9. Skoog G, Skoog I. A 40-year follow-up of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 2021;56:121-7.
10. Menchand;oacute;n JM, Real E, Alonso P, Aparicio MA, Segalas C, Plans G, et al. A prospective international multi-center study on safety and efficacy of deep brain stimulation for resistant obsessive-compulsive disorder. Mol Psychiatry 2019;26:1234-47.
11. Mataix-Cols D, Frost RO, Pertusa A, Clark LA, Saxena S, Leckman JF, et al. Hoarding disorder: A new diagnosis for DSM-V? Depress Anxiety 2010;27:556-72.
12. Twohig MP, Abramowitz JS, Smith BM, Fabricant LE, Jacoby RJ, Morrison KL, et al. Adding acceptance and commitment therapy to exposure and response prevention for obsessive-compulsive disorder: A randomized controlled trial. Behav Res Ther 2018;108:1-9.</References>
</References>
</Journal>
</Article>
</ArticleSet>